🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,80 EUR

Máx. histórico

912,40

64 días

Caída desde máximo

-10,59%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,03%

Cierre anterior

815,60

Rango de hoy

788,80 – 815,80

Volumen hoy

102.849

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,83 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
1.005,32 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 1 día
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
02/08/2021 258,00 261,80 253,50 261,00 +1,44% 3,22% 35.823
30/07/2021 245,30 258,10 242,20 257,30 +1,42% 6,48% 57.829
29/07/2021 259,00 260,40 247,10 253,70 -1,13% 5,14% 60.570
28/07/2021 252,50 258,50 247,30 256,60 +2,19% 4,44% 71.247
27/07/2021 258,00 258,10 250,10 251,10 -4,09% 3,10% 63.242
26/07/2021 267,90 269,00 260,30 261,80 -2,28% 3,25% 43.288
23/07/2021 271,60 273,40 265,70 267,90 -1,33% 2,84% 30.182
22/07/2021 269,20 278,20 269,00 271,50 +1,42% 3,42% 55.243
21/07/2021 261,20 268,40 260,30 267,70 +2,88% 3,10% 53.060
20/07/2021 265,80 266,20 256,80 260,20 -1,55% 3,54% 74.995
19/07/2021 265,00 266,70 257,10 264,30 +2,05% 3,62% 78.605
16/07/2021 255,80 259,90 253,40 259,00 +1,29% 2,54% 44.265
15/07/2021 258,00 259,00 252,60 255,70 -1,39% 2,48% 39.690
14/07/2021 260,50 263,00 258,10 259,30 -0,61% 1,88% 33.098
13/07/2021 260,80 263,70 256,30 260,90 -0,80% 2,84% 44.516
12/07/2021 262,00 267,00 259,90 263,00 +0,42% 2,71% 37.153
09/07/2021 264,40 265,10 255,70 261,90 +0,85% 3,56% 51.983
08/07/2021 262,00 265,00 258,00 259,70 -1,18% 2,67% 46.262
07/07/2021 264,40 266,00 261,00 262,80 -0,45% 1,89% 53.309
06/07/2021 256,40 265,80 255,70 264,00 +2,52% 3,94% 57.155
05/07/2021 266,90 266,90 257,10 257,50 -1,87% 3,67% 27.859
02/07/2021 257,10 263,50 257,10 262,40 +3,67% 2,49% 53.372
01/07/2021 256,10 257,90 250,70 253,10 -0,78% 2,81% 56.367
30/06/2021 262,20 265,90 254,50 255,10 -2,89% 4,35% 62.697
29/06/2021 265,00 267,20 262,30 262,70 -1,46% 1,85% 37.836
28/06/2021 265,60 267,90 262,10 266,60 +0,15% 2,18% 54.224
25/06/2021 264,00 269,50 263,50 266,20 -0,15% 2,27% 58.149
24/06/2021 261,10 268,40 259,50 266,60 +2,38% 3,41% 69.105
23/06/2021 265,00 267,00 260,00 260,40 -2,47% 2,64% 35.913
22/06/2021 267,00 271,90 265,60 267,00 -0,19% 2,36% 45.695